The article examines how some Australian online wellness and longevity clinics are supplying unapproved peptides and anti-ageing injections by relying on legal exemptions intended for limited clinical circumstances.

While a small number of peptides, such as insulin, are approved medicines, many products marketed by these clinics, including BPC-157, CJC-1295 and TB-500, have not been approved by the Therapeutic Goods Administration (TGA).

According to the article, there is no reliable clinical evidence demonstrating that these products deliver the anti-ageing, muscle-building, recovery or sleep benefits promoted to consumers, while the TGA has warned they may pose significant health risks.

The article explains that clinics often make use of pharmacy compounding exemptions, which were designed for preparing customised medicines for individual patients rather than producing large quantities of injectable products for widespread distribution.

This creates a regulatory gap between the TGA, which regulates therapeutic goods, and Ahpra, which oversees the conduct of registered health practitioners.Although both regulators have strengthened aspects of prescribing and compounding rules, enforcement can be slow and fragmented.

The article also highlights concerns about product quality, sterility, dosing accuracy and possible health consequences, including elevated IGF-1 levels associated with some peptides.It notes that these treatments are often expensive, with only a few weeks' supply costing more than A$1,000.

The author argues that stronger enforcement of existing advertising laws, increased regulatory resources and tighter restrictions on large-scale compounding would better protect consumers without requiring entirely new legislation.